Neurology
RSSArticles
-
Lipid Pathway Dysfunction in Parkinson’s Disease
In this large-scale study, the authors used a comprehensive untargeted lipidomic approach to determine the extent to which lipid dysregulation occurs in patients with Parkinson’s disease generally and in mutation carriers of one of the most common Parkinson’s disease risk genes, LRRK2. Further pathway analysis reveals sphingolipid metabolism, insulin signaling, and mitochondrial function as major metabolic pathways dysregulated in Parkinson’s disease.
-
Persistent Asthma Patients Show More Plaque Buildup, Inflammation
Pulmonary ailment could speed carotid artery damage, create more inflammatory biomarkers.
-
Acute Ataxia and Gait Disturbances in the Emergency Department
Ataxia and gait disturbances can signify a variety of conditions. The differential includes benign as well as life-threatening causes. An understanding of the pathophysiology and a thorough neurological exam are critical in making these distinctions.
-
Medical Incapacity Holds Require Ethical Oversight
Clinicians feel conflicted about their ethical obligations. On one hand, they know it is unsafe for a confused person to be allowed to walk out of the hospital. On the other hand, they are understandably worried about their legal risks.
-
Benefits, Risks of Dual Antiplatelet Therapy After Acute Ischemic Stroke or TIA
It will be important to determine the actual frequency of the CYP2C19 loss-of-function gene. Clinicians should consider point-of-care testing for patients before selecting and initiating dual antiplatelet therapy.
-
Long-Term Outcomes in Intracerebral, Intraventricular Hemorrhage
It is important to avoid giving a poor prognosis early in the clinical course, and to continue supportive care until the long-term outcome truly is understood.
-
Sodium Phenylbutyrate and Taurursodiol for Oral Suspension (Relyvrio)
Relyvrio can be prescribed to treat amyotrophic lateral sclerosis in adults.
-
Scientists Are Worried About Air Quality and Dementia Risk
Traffic-related air pollution raises red flags for neurological health.
-
Is IVIG Treatment Really Better than Natural Recovery in Patients with Guillain-Barré Syndrome?
In this controversial report comparing patients with Guillain-Barré syndrome treated with intravenous immunoglobulin vs. no treatment, the group that appears to have fared the best were patients who had an acute demyelinating syndrome, and not an axonal variant. This was an observational study and not a randomized treatment trial.
-
Intravenous Immunoglobulin in Dermatomyositis
Treatment of dermatomyositis with intravenous immunoglobulin (IVIG) resulted in overall better clinical improvement after 16 weeks compared to patients treated with placebo. However, there was a significant number of thromboembolic adverse events in the treatment group. The group of patients treated was a heterogeneous group. However, IVIG now is U.S. Food and Drug Administration-approved for the treatment of dermatomyositis.